In cell-line and mouse models of ovarian cancer, researchers developed an interdisciplinary approach to identify metabolic vulnerabilities in certain genes that could be targeted to kill cancer cells.

Clinical guidelines have encouraged the integration of palliative care, yet medicine lags far behind its goals for ovarian cancer, especially for people of color.

In cell and mouse models, miR181a showed promise as a biomarker for early stage ovarian cancer and may help make immunotherapy treatment more effective.

Three early-stage cancer drug projects receive pilot grants to help them advance from the bench toward the bedside.

A new study sheds light on the risk of blood clots at all stages of ovarian cancer and the potential need for preventive blood thinners during pre-surgery chemotherapy.

The finding suggests a potential therapy to slow the disease in patients or a possible preventive strategy for women at high risk for ovarian cancer.